Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human LATS1 Antibodies:
anti-Mouse (Murine) LATS1 Antibodies:
anti-Rat (Rattus) LATS1 Antibodies:
Go to our pre-filtered search.
Human Polyclonal LATS1 Primary Antibody for IP, WB - ABIN5665731
Lee, Kim, Yang, Koo, Oh, Lee, Oh, Lee, Kong, Kim, Lim: A crucial role of WW45 in developing epithelial tissues in the mouse. in The EMBO journal 2008
Show all 6 Pubmed References
Human Polyclonal LATS1 Primary Antibody for IF (p), IHC (p) - ABIN872292
Grijalva, Huizenga, Mueller, Rodriguez, Brazzo, Camargo, Sadri-Vakili, Vakili: Dynamic alterations in Hippo signaling pathway and YAP activation during liver regeneration. in American journal of physiology. Gastrointestinal and liver physiology 2014
Human Polyclonal LATS1 Primary Antibody for IHC (p), WB - ABIN391033
Iida, Hirota, Morisaki, Marumoto, Hara, Kuninaka, Honda, Kosai, Kawasuji, Pallas, Saya: Tumor suppressor WARTS ensures genomic integrity by regulating both mitotic progression and G1 tetraploidy checkpoint function. in Oncogene 2004
Show all 6 Pubmed References
Human Polyclonal LATS1 Primary Antibody for IP, WB - ABIN4891893
Xiang, Gilkes, Hu, Takano, Luo, Lu, Bullen, Samanta, Liang, Semenza: Hypoxia-inducible factor 1 mediates TAZ expression and nuclear localization to induce the breast cancer stem cell phenotype. in Oncotarget 2015
lncARSR interacts with Yes-associated protein (YAP (show YAP1 Antibodies)) to block its phosphorylation by LATS1, facilitating YAP (show YAP1 Antibodies) nuclear translocation.
LATS1 is an independent prognostic factor and may play an important role in non-Small Cell Lung Cancer progression and may serve as a novel therapeutic target of non-Small Cell Lung Cancer.
Increased miR (show MLXIP Antibodies)-424 expression or decreased LATS1 expression was associated with pathological stage and unfavorable prognosis of GC patients.
Deregulation of LATS1 and YAP1 (show YAP1 Antibodies) expression is associated with clear cell renal cell carcinoma (show MOK Antibodies) progression and poor patient survival.
In the present study, we investigated the expression of activated core Hippo pathway kinases (pMST1/2 and pLATS1/2) in a series of 57 HER2 (show ERBB2 Antibodies)-positve and triple-negative breast cancer patients who received neoadjuvant therapy .
LATS1/2 signaling via the Hippo pathway regulates human megakaryocytic differentiation.
Our findings suggest that LATS1 is a potential candidate tumor suppressor and inhibits the growth and metastasis of gastric carcinoma cells via downregulation of the YAP (show YAP1 Antibodies) signaling.
Low LATS1 expression is associated with breast cancer.
Loss of LATS1 expression is associated with pancreatic cancer.
TNFAIP8 (show TNFAIP8 Antibodies) regulates Hippo (MST1 (show MST1 Antibodies)/2) signaling through its interaction with LATS1.
During and after liver development, the activation of YAP (show YAP1 Antibodies)/TAZ (show TAZ Antibodies) induced by loss of Lats1/2 forces hepatoblasts or hepatocytes to commit to the biliary epithelial cell lineage.
Epicardial Deletion of Lats1 gene Results in Defective Coronary Vessel Development.
Collectively, these data indicate that Yap (show YAP1 Antibodies)-induced Epiregulin (show EREG Antibodies) signaling promotes the identity of submandibular gland ductal progenitors and that removal of nuclear Yap (show YAP1 Antibodies) by Lats1/2-mediated signaling is critical for proper ductal maturation.
Study demonstrates that, in 3 different murine syngeneic tumor models (B16, SCC7, and 4T1), loss of the Hippo pathway kinases LATS1/2 (large tumor suppressor 1 and 2) in tumor cells inhibits tumor growth; data indicate a new paradigm for how tumor immunogenicity is regulated through the Hippo signaling pathway in tumor cells.
Results showed that the Hippo pathway is active in ovarian follicles and that LATS1 is required to maintain the pool of germ cells and primordial follicles.
The control of LATS activation by angiotensin II and subsequent YAP (show YAP1 Antibodies) localization is important for podocyte homeostasis and survival.
Willin (show FRMD6 Antibodies) is predominantly expressed in fibroblasts and that Willin (show FRMD6 Antibodies) expression activates the Hippo signaling cascade
LATS1 tumor suppressor is a novel actin-binding protein and negative regulator of actin polymerization.
KIBRA (show WWC1 Antibodies) associates with and activates Lats (large tumor suppressor) 1 and 2 kinases by stimulating their phosphorylation on the hydrophobic motif
Lats1 enhances the activity of FOXl2 (show FOXL2 Antibodies) as a repressor of the StAr promoter. st
Thus AMOT (show AMOT Antibodies) is a direct substrate of Lats1/2 mediating functions of the Hippo pathway in endothelial cell migration and angiogenesis.
lats genes show distinctly different expression profiles during gastrulation. lats1 is almost ubiquitously expressed through development, and lats2 is more prominently expressed in the non-neural ectoderm region of zebrafish gastrula.
The protein encoded by this gene is a putative serine/threonine kinase that localizes to the mitotic apparatus and complexes with cell cycle controller CDC2 kinase in early mitosis. The protein is phosphorylated in a cell-cycle dependent manner, with late prophase phosphorylation remaining through metaphase. The N-terminal region of the protein binds CDC2 to form a complex showing reduced H1 histone kinase activity, indicating a role as a negative regulator of CDC2/cyclin A. In addition, the C-terminal kinase domain binds to its own N-terminal region, suggesting potential negative regulation through interference with complex formation via intramolecular binding. Biochemical and genetic data suggest a role as a tumor suppressor. This is supported by studies in knockout mice showing development of soft-tissue sarcomas, ovarian stromal cell tumors and a high sensitivity to carcinogenic treatments.
LATS (large tumor suppressor, Drosophila) homolog 1
, LATS, large tumor suppressor, homolog 1
, WARTS protein kinase
, large tumor suppressor homolog 1
, serine/threonine-protein kinase LATS1
, large tumor supressor, homolog 1
, large tumor suppressor 1
, large tumor suppressor
, LATS homolog 1
, LATS, large tumor suppressor, homolog 1 (Drosophila)
, serine/threonine-protein kinase LATS1-like
, large tumor suppressor kinase 1 S homeolog